Production (Stage)
Ikena Oncology, Inc.
IKNA
$1.43
$0.064.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -88.75% | -61.48% | -67.91% | -53.47% | -97.18% |
| Gross Profit | 88.75% | 61.48% | 66.36% | 49.38% | 96.72% |
| SG&A Expenses | -16.80% | -5.92% | -8.42% | -20.83% | -0.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.25% | -40.18% | -46.05% | -43.95% | -26.12% |
| Operating Income | 44.25% | 40.18% | 44.43% | 40.55% | 18.12% |
| Income Before Tax | 79.87% | 46.70% | 53.84% | 41.05% | 20.14% |
| Income Tax Expenses | -75.81% | 3.70% | 132.72% | -- | -- |
| Earnings from Continuing Operations | 79.85% | 46.62% | 53.18% | 40.99% | 19.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.85% | 46.62% | 53.18% | 40.99% | 19.78% |
| EBIT | 44.25% | 40.18% | 44.43% | 40.55% | 18.12% |
| EBITDA | 44.48% | 39.89% | 44.05% | 40.27% | 17.54% |
| EPS Basic | 79.86% | 46.62% | 53.55% | 46.88% | 34.69% |
| Normalized Basic EPS | 81.21% | 47.12% | 55.91% | 51.14% | 38.21% |
| EPS Diluted | 79.86% | 46.62% | 53.55% | 46.88% | 34.69% |
| Normalized Diluted EPS | 81.21% | 47.12% | 55.91% | 51.14% | 38.21% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.80% | 11.10% | 22.82% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.80% | 11.10% | 22.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |